Mental Health Services

(asked on 16th October 2014) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions.


Answered by
George Freeman Portrait
George Freeman
This question was answered on 21st October 2014

The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.

Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:

Appraisal Number

Year

Technology

Condition

Categorisation

TA59

2003

Electroconvulsive therapy

Catatonia/ prolonged or severe manic episode

Optimised1

TA098

2006

Atomoxetine

Attention deficit hyperactivity disorder (ADHD)

Recommended

TA098

2006

Dexamfetamine

Attention deficit hyperactivity disorder (ADHD)

Recommended

TA098

2006

Methylphenidate

Attention deficit hyperactivity disorder (ADHD)

Recommended

TA213

2011

Aripiprazole

Schizophrenia in people aged 15-17 years

Recommended

TA217

2011

Donepezil

Alzheimer's disease (mild to moderate)

Recommended

TA217

2011

Galantamine

Alzheimer's disease (mild to moderate)

Recommended

TA217

2011

Rivastigmine

Alzheimer's disease (mild to moderate)

Recommended

TA217

2011

Memantine

Alzheimer's disease (moderate)

Optimised

TA217

2011

Memantine

Alzheimer's disease (severe)

Recommended

TA292

2013

Aripiprazole

Moderate to severe manic episodes in adolescents with bipolar disorder

Recommended

Source: National Institute for Health and Care Excellence

1 The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.

Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.

Details of all NICE’s guidance on mental health and behavioural conditions can be found at:

www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions

Reticulating Splines